natgillin/translations-raw huggingface dataset:
Unless otherwise decided by the Governing Council, the ECB shall distribute to the NCBs its income on euro banknotes in circulation accrued and its income arising from securities earned in each financial year on the last working day in January of the following year.
Če Svet ECB ne odloči drugače, ECB med nacionalne centralne banke razdeli svoj prihodek iz naslova eurobankovcev v o btoku in svoj prihodek iz naslova vrednostnih papirjev, ki nastaneta v vsakem poslovnem letu, na zadnji delovni dan v januarju naslednjega leta.
The amount of the ECB's income on euro banknotes in circulation may be reduced in accordance with any decision by the Governing Council on the basis of the Statute of the ESCB in respect of expenses incurred by the ECB in connection with the issue and handling of euro banknotes.
Znesek prihodka ECB iz naslova eurobankovcev v obtoku se lahko v skladu s sklepom Sveta ECB na podlagi Statuta ESCB zmanjša glede na stroške, ki jih ima ECB v zvezi z izdajo in obdelavo eurobankovcev.
By way of derogation from Article 2, the Governing Council shall decide before the end of the financial year whether all or part of the ECB's income referred to in that Article should be retained to the extent necessary to ensure that the amount of the distributed income does not exceed the ECB's net profit for that year.
Z odstopanjem od člena 2 Svet ECB pred koncem poslovnega leta odloči, ali se prihodek ECB iz navedenega člena v celoti ali delno zadrži v obsegu, ki je potreben za to, da znesek razdeljenega prihodka ne preseže čistega dobička ECB za tisto leto.
Any such decision shall be taken where, on the basis of a reasoned estimate prepared by the Executive Board, the Governing Council expects that the ECB will have an overall annual loss or will make an annual net profit that is less than the estimated amount of its income referred to in Article 2.
Taka odločitev se sprejme, kadar Svet ECB na podlagi obrazložene ocene, ki jo pripravi Izvršilni odbor, pričakuje, da bo ECB imela skupno letno izgubo ali da bo ustvarila letni čisti dobiček, ki bo manjši od ocenjenega zneska njenega prihodka iz člena 2.
The Governing Council may decide before the end of the financial year to transfer all or part of the ECB's income referred to in that Article to a provision for foreign exchange rate, interest rate, credit and gold price risks.
Svet ECB lahko pred koncem poslovnega leta odloči, da se prihodek ECB iz navedenega člena v celoti ali delno prenese v rezervacije za tveganje deviznega tečaja, obrestno in kreditno tveganje ter tveganje cene zlata.
This Decision shall enter into force on 31 December 2014.
Ta sklep začne veljati 31. decembra 2014.
Decision ECB/2010/24 is repealed with effect from 31 December 2014.
Sklep ECB/2010/14 se razveljavi z učinkom od 31. decembra 2014.
References to Decision ECB/2010/24 shall be construed as references to this Decision.
Sklicevanja na Sklep ECB/2010/24 se štejejo za sklicevanja na ta sklep.
Done at Frankfurt am Main, 15 December 2014.
V Frankfurtu na Majni, 15. decembra 2014
Decision ECB/2010/24 of 25 November 2010 on the interim distribution of the income of the European Central Bank on euro banknotes in circulation and arising from securities purchased under the securities markets programme (OJ L 6, 11.1.2011, p. 35).
Sklep ECB/2010/24 z dne 25. novembra 2010 o vmesni razdelitvi prihodka Evropske centralne banke iz naslova eurobankovcev v obtoku in iz naslova vrednostnih papirjev, kupljenih po programu v zvezi s trgi vrednostnih papirjev (UL L 6, 11.1.2011, str. 35).
Decision ECB/2014/40 of 15 October 2014 on the implementation of the third covered bond purchase programme (OJ L 335, 22.11.2014, p. 22).
Sklep ECB/2014/40 z dne 15. oktobra 2014 o izvajanju tretjega programa nakupa kritih obveznic (UL L 335, 22.11.2014, str. 22).
Decision (EU) 2015/5 of 19 November 2014 on the implementation of the asset-backed securities purchase programme (ECB/2014/45) (OJ L 1, 6.1.2015, p. 4).
Sklep Evropske centralne banke (EU) 2015/5 z dne 19. novembra 2014 o izvajanju programa nakupa listinjenih vrednostnih papirjev (ECB/2014/45) (UL L 1, 6.1.2015, str. 4).
Decision ECB/2010/29 of 13 December 2010 on the issue of euro banknotes (OJ L 35, 9.2.2011, p. 26).
Sklep ECB/2010/29 z dne 13. decembra 2010 o izdajanju eurokovancev (UL L 35, 9.2.2011, str. 26).
Decision ECB/2010/23 of 25 November 2010 on the allocation of monetary income of the national central banks of Member States whose currency is the euro (OJ L 35, 9.2.2011, p. 17).
Sklep ECB/2010/23 z dne 25. novembra 2010 o razporeditvi denarnih prihodkov nacionalnih centralnih bank držav članic, katerih valuta je euro (UL L 35, 9.2.2011, str. 17).
Decision ECB/2010/5 of 14 May 2010 establishing a securities markets programme (OJ L 124, 20.5.2010, p.
Sklep ECB/2010/5 z dne 14. maja 2010 o vzpostavitvi programa v zvezi s trgi vrednostnih papirjev (UL L 124, 20.5.2010, str.
approving restrictions of the authorisation of one biocidal product containing difenacoum notified by Germany in accordance with Directive 98/8/EC of the European Parliament and of the Council
o odobritvi omejitev dovoljenja za biocidni proizvod, ki vsebuje difenakum in ki ga je Nemčija priglasila v skladu z Direktivo 98/8/ES Evropskega parlamenta in Sveta
(notified under document C(2014) 496)
(notificirano pod dokumentarno številko C(2014) 496)
Commission Directive 2008/81/EC [2] added the active substance difenacoum for use in products belonging to product-type 14, Rodenticides, as defined in Annex V to Directive 98/8/EC.
Z Direktivo Komisije 2008/81/ES [2] je bila dodana aktivna snov difenakum za uporabo v 14. vrsti proizvodov (rodenticidi), kot je opredeljena v Prilogi V k Direktivi 98/8/ES.
Difenacoum is an anticoagulant rodenticide known to pose risks of accidental incidents with children, as well as risks for non-target animals and the environment.
Difenakum je antikoagulantni rodenticid, pri katerem je znano, da lahko predstavlja tveganje za naključne nesreče z otroki ter tudi tveganje za neciljne živali in okolje.
For reasons of public health and hygiene, it was nevertheless found to be justified to include difenacoum and other anticoagulant rodenticides in Annex I to Directive 98/8/EC, thus allowing Member States to authorise difenacoum-based products.
Zaradi javnega zdravja in higiene je bilo kljub temu ugotovljeno, da je upravičeno vključiti difenakum in druge antikoagulantne rodenticide v Prilogo I k Direktivi 98/8/ES, kar državam članicam omogoča, da odobrijo proizvode na osnovi difenakuma.
However, Member States were obliged to ensure, when granting authorisation of products containing difenacoum, that primary as well as secondary exposure of humans, non-target animals and the environment is minimised, by considering and applying all appropriate and available risk mitigation measures.
Vendar pa bi morale države članice zagotoviti, da se pri izdaji dovoljenj za proizvode, ki vsebujejo difenakum, zmanjšata primarna in sekundarna izpostavljenost ljudi, neciljnih živali in okolja z upoštevanjem in izvajanjem vseh ustreznih in razpoložljivih ukrepov za zmanjšanje tveganja.
The risk mitigation measures mentioned in Directive 2008/81/EC therefore include, amongst others, restriction to professional use only.
Ukrepi za zmanjšanje tveganja iz Direktive 2008/81/ES zato med drugim vključujejo omejitev na samo poklicno uporabo.
The company VEBI Istituto Biochimico S.r.l.
Podjetje VEBI Istituto Biochimico S.r.l.
(‘the applicant’) has, in accordance with Article 8 of Directive 98/8/EC, submitted one application to Italy for authorisation of one rodenticide containing difenacoum (‘the product’).
(v nadaljnjem besedilu: vložnik) je v skladu s členom 8 Direktive 98/8/ES Italiji predložilo vlogo za odobritev enega rodenticida, ki vsebuje difenakum (v nadaljnjem besedilu: proizvod).
On 18 February 2013, the applicant submitted a complete application to Germany for mutual recognition of the first authorisation in respect of the product.
Vložnik je 18. februarja 2013 Nemčiji predložil popolno vlogo za medsebojno priznavanje prvega dovoljenja za proizvod.
On 12 June 2013, Germany notified the Commission, the other Member States and the applicant of its proposal to restrict the first authorisation in accordance with Article 4(4) of Directive 98/8/EC.
Nemčija je 12. junija 2013 Komisijo, druge države članice in vložnika obvestila o svojem predlogu za omejitev prvega dovoljenja v skladu s členom 4(4) Direktive 98/8/ES.
The notification was also discussed between the Commission and Member States’ Competent Authorities for biocidal products in the meeting of the Product Authorisation and Mutual Recognition Facilitation Group of 9 July 2013.
Obvestilo so obravnavali tudi Komisija in organi držav članic, pristojni za biocidne proizvode, na srečanju Skupine za poenostavitev medsebojnega priznavanja in izdajo dovoljenj za proizvode 9. julija 2013.
In accordance with Directive 98/8/EC, authorisations of biocidal products containing difenacoum are to be subject to all appropriate and available risk mitigation measures, including the restriction to professional use only.
V skladu z Direktivo 98/8/ES bi bilo treba za odobritev biocidnih proizvodov, ki vsebujejo difenakum, upoštevati vse ustrezne in razpoložljive ukrepe za zmanjšanje tveganja, vključno z omejitvijo na samo poklicno uporabo.
The scientific evaluation leading to the inclusion of difenacoum in Directive 98/8/EC concluded that only professional users could be expected to follow the instructions minimising the risk of secondary poisoning of non-target animals, and to use products in a way that prevents the selection and spreading of resistance.
Glede na znanstveno oceno za vključitev difenakuma v Direktivo 98/8/ES se lahko le od poklicnih uporabnikov pričakuje upoštevanje navodil in s tem zmanjšanje tveganja sekundarne zastrupitve neciljnih živali ter uporaba proizvodov na način, ki preprečuje selekcijo in širjenje odpornosti.
A restriction to professional users should therefore in principle be considered to be an appropriate risk mitigation measure, in particular in Member States where resistance to difenacoum occurs.
Omejitev uporabe na poklicne uporabnike bi zato morala načeloma veljati za ustrezen ukrep za zmanjšanje tveganja, zlasti v državah članicah, kjer se pojavlja odpornost na difenakum.
In the absence of any indication to the contrary, restriction to professional users is therefore an appropriate and available risk mitigation measure for the authorisation of products containing difenacoum in Germany.
Ker ni dokaza o nasprotnem, je omejitev uporabe na poklicne uporabnike primeren in razpoložljiv ukrep za zmanjšanje tveganja pri odobritvi proizvodov, ki vsebujejo difenakum, v Nemčiji.
This conclusion is reinforced by the arguments put forward by Germany that resistance against difenacoum in rats has been found and is thought to be developing in the country.
To ugotovitev potrjujejo tudi argumenti Nemčije o ugotovljeni odpornosti proti difenakumu pri podganah in njenem domnevnem širjenju po državi.
Commission Directive 2008/81/EC of 29 July 2008 amending Directive 98/8/EC of the European Parliament and of the Council to include difenacoum as an active substance in Annex I thereto (OJ L 201, 30.7.2008, p. 46).
Direktiva Komisije 2008/81/ES z dne 29. julija 2008 o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev difenakuma kot aktivne snovi v Prilogo I k Direktivi (UL L 201, 30.7.2008, str. 46).
Product name in Italy
Ime proizvoda v Italiji
Italian application reference number in the Register for Biocidal Products
Referenčna številka vloge v registru biocidnih proizvodov v Italiji
Italy granted the authorisation of the product on 20 December 2012.
Italija je 20. decembra 2012 izdala dovoljenje za proizvod.
The product was authorised with restrictions to ensure that the conditions of Article 5 of Directive 98/8/EC were met in Italy.
Proizvod je bil odobren z omejitvami, da se zagotovi upoštevanje pogojev iz člena 5 Direktive 98/8/ES v Italiji.
of 5 February 2014
z dne 5. februarja 2014
on the safety requirements to be met by European standards for consumer laser products pursuant to Directive 2001/95/EC of the European Parliament and of the Council on general product safety
o varnostnih zahtevah, ki jih morajo izpolnjevati evropski standardi za potrošniške laserske proizvode v skladu z Direktivo 2001/95/ES Evropskega parlamenta in Sveta o splošni varnosti proizvodov
Products covered by Directive 2001/95/EC which conform to national standards transposing European standards drawn up under that Directive benefit from a presumption of safety as far as the risks covered by the standards are concerned.
Za proizvode iz Direktive 2001/95/ES, ki so v skladu z nacionalnimi standardi, ki prevzemajo evropske standarde in so bili pripravljeni v okviru navedene direktive, se domneva, da so varni glede tveganj, zajetih v standardih.
European standards are to be drawn up on the basis of safety requirements intended to ensure that products which conform to the standards satisfy the general safety requirement set out in Article 3 of Directive 2001/95/EC.
Evropske standarde se pripravi na podlagi varnostnih zahtev, katerih namen je zagotoviti, da proizvodi, ki so v skladu s standardi, izpolnjujejo splošno varnostno zahtevo iz člena 3 Direktive 2001/95/ES.
Laser products, in particular hand-held, battery-powered laser pointers, that pose a risk of damage to sight and to the skin have become widely available to consumers.
Laserski proizvodi, še zlasti ročni baterijski laserski kazalniki, ki predstavljajo tveganje poškodbe vida in kože, so postali dostopni širšemu krogu potrošnikov.
The current European standard for laser products (EN 60825-1:2007 ‘Safety of laser products – Part 1: Equipment classification and requirements’) provides that the hazard of laser products has to be assessed and that laser products have to carry appropriate warning labels and be supplied with user instructions that contain all relevant safety information.
Veljavni evropski standard za laserske proizvode (EN 60825-1:2007 „Varnost laserskih izdelkov – 1. del: Klasifikacija opreme in zahteve“) določa, da je treba oceniti tveganje laserskih proizvodov ter da morajo biti laserski proizvodi opremljeni z ustreznimi opozorilnimi oznakami in navodili za uporabo, ki vsebujejo vse pomembne varnostne informacije.
However, compliance with that standard does not ensure that a laser product is safe to be used by consumers.
Vendar upoštevanje tega standarda ne zagotavlja varnosti laserskega proizvoda za potrošnike.
Currently there is a widespread consensus that laser products corresponding to classes 1, 1M, 2 and 2M of the classification put in place by the standard referred to in recital 4 can be considered safe when used by consumers (provided that exposure to laser radiation does not take place with optical viewing instruments in case of products corresponding to classes 1M and 2M).
Trenutno obstaja splošno soglasje, da se laserski proizvodi, ki spadajo v razrede 1, 1M, 2 in 2M klasifikacije, vzpostavljene v okviru standarda iz uvodne izjave 4, lahko štejejo za varne za potrošniško uporabo (če ne pride do izpostavljenosti laserskemu sevanju pri optičnih opazovalnih instrumentih v primeru proizvodov iz razredov 1M in 2M).
This is not the case however for laser products of other laser classes.
Vendar to ne velja za laserske proizvode iz drugih laserskih razredov.
European standards should be drawn up in such a way as not to hamper technical innovation.
Evropske standarde bi bilo treba oblikovati tako, da ne ovirajo tehničnih inovacij.
For this reason, any standard for consumer laser products should not ban completely any products as far as the products can be used safely, bearing in mind that any damage to the eyes or unintended damage to the skin, whether reversible or irreversible, is incompatible with a high level of consumer health and safety protection.
Zato noben standard za potrošniške laserske proizvode ne bi smel popolnoma prepovedovati nobenega proizvoda, če se ta lahko varno uporablja, ob upoštevanju, da kakršne koli reverzibilne ali ireverzibilne poškodbe oči oziroma nenamerne poškodbe kože niso združljive z visoko ravnjo varovanja zdravja in zaščite potrošnikov.
It is therefore appropriate to determine the safety requirements for consumer laser products in order to be able to submit a request to the European standardisation bodies to develop a new European standard or amend the current European standard.
Zato je primerno določiti varnostne zahteve za potrošniške laserske proizvode, da bi bilo evropskim standardizacijskim organom mogoče predložiti zahtevek za oblikovanje novega ali spremembo veljavnega evropskega standarda.
The measures provided for in this Decision are in accordance with the opinion of the Committee on General Product Safety,
Ukrepi iz tega sklepa so v skladu z mnenjem Odbora za splošno varnost proizvodov –
‘consumer laser product’ means any product or assembly of components that:
je „potrošniški laserski proizvod“ vsak proizvod ali sklop komponent, ki:
is intended for consumers, or likely to be used by consumers under reasonably foreseeable conditions even if not intended for them; and
je namenjen potrošnikom ali ga bodo potrošniki najverjetneje uporabljali v razumnih predvidljivih pogojih, čeprav jim ta ni namenjen, ter
constitutes or incorporates a laser or laser system and during operation permits access to laser radiation;
pomeni ali vključuje laser ali laserski sistem in med uporabo omogoča lasersko sevanje;
‘child appealing consumer laser product’ means a consumer laser product that:
je „otrokom privlačen potrošniški laserski proizvod“ potrošniški laserski proizvod, ki:
resembles, by virtue of its form or design, anything that is commonly recognized as being appealing to, or intended for use by, children; or
je po obliki ali zasnovi podoben nečemu, kar je splošno prepoznavno kot privlačno ali namenjeno otrokom ali
has any other feature or characteristic, not necessary for the function of the product, that is likely to be appealing to children;
ima kakršno koli drugo lastnost ali značilnost, ki ni nujno potrebna za delovanje proizvoda, in za katero je verjetno, da bo privlačna za otroke;
‘damage to the eyes or the skin’ means any effect of laser radiation detrimental to the structure or function of the eyes or the skin, whether reversible or irreversible.
je „poškodba oči ali kože“ kakršen koli reverzibilen ali ireverzibilen učinek laserskega sevanja, ki škoduje zgradbi ali delovanju oči oziroma kože.
The safety requirements to be met by European standards for consumer laser products pursuant to Directive 2001/95/EC shall be the following:
Varnostne zahteve, ki jih morajo izpolnjevati evropski standardi za potrošniške laserske proizvode v skladu z Direktivo 2001/95/ES, so:
child appealing consumer laser products shall not cause damage to the eyes or the skin in case of any exposure to laser radiation that could occur under any conditions of use, including deliberate long-term exposure with optical viewing instruments;
otrokom privlačen potrošniški laserski proizvod ne povzroča poškodb oči ali kože v primeru izpostavljenosti laserskemu sevanju v kakršnih koli pogojih uporabe, vključno z namerno dolgoročno izpostavljenostjo pri optičnih opazovalnih instrumentih;
all other consumer laser products shall not cause damage to the eyes or unintended damage to the skin in case of any exposure to laser radiation that could occur under normal or reasonably foreseeable conditions of use, including momentary accidental or unintentional exposure; any intended damage to the skin caused by consumer laser products shall be compatible with a high level of consumer health and safety protection;
drugi potrošniški laserski proizvodi prav tako ne povzročajo poškodb oči ali nenamernih poškodb kože v primeru izpostavljenosti laserskemu sevanju v običajnih ali razumnih predvidljivih pogojih uporabe, vključno s kratkotrajno naključno in nenamerno izpostavljenostjo; vsaka namerna poškodba kože, ki jo povzročijo potrošniški laserski proizvodi, je združljiva z visoko ravnjo varovanja zdravja in zaščite potrošnikov;
conformity with points 1 and 2 shall be achieved by technical means;
skladnost s točkama 1 in 2 se doseže s tehničnimi sredstvi;
in the case of products that conform with point 2, if exposure to laser radiation that would cause damage to the eyes or the skin could occur under conditions of use other than those referred to in point 2, those products shall carry appropriate warning labels and shall be supplied with user instructions that contain all relevant safety information.
če je izpostavljenost laserskemu sevanju, ki bi lahko poškodovalo oči ali kožo, mogoča v pogojih uporabe, ki ne vključujejo tistih iz točke 2, bi morali biti proizvodi, skladni s točko 2, opremljeni z ustrezno opozorilno oznako in navodili za uporabo, ki vsebujejo vse pomembne varnostne informacije.
Done at Brussels, 5 February 2014.
V Bruslju, 5. februarja 2014
Decision (EU) 2015/433 of the European Central Bank
Sklep Evropske centralne banke (EU) 2015/433
of 17 December 2014
z dne 17. decembra 2014
concerning the establishment of an Ethics Committee and its Rules of Procedure (ECB/2014/59)
o ustanovitvi Odbora za poklicno etiko in sprejetju njegovega poslovnika (ECB/2014/59)
Having regard to Decision ECB/2004/2 of 19 February 2004 adopting the Rules of Procedure of the European Central Bank [1], and in particular Article 9a thereof,
ob upoštevanju Sklepa ECB/2004/2 z dne 19. februarja 2004 o sprejetju Poslovnika Evropske centralne banke [1] in zlasti člena 9a Sklepa,
Through the establishment of an Ethics Committee of the European Central Bank (hereinafter the ‘Ethics Committee’), the Governing Council aims to strengthen the ethics rules in place and further enhance the corporate governance of the European Central Bank (ECB), the European System of Central Banks (ESCB), the Eurosystem and the Single Supervisory Mechanism (SSM).
Svet Evropske centralne banke (ECB) namerava z ustanovitvijo Odbora ECB za poklicno etiko (v nadaljnjem besedilu: Odbor za poklicno etiko) okrepiti veljavna etična pravila in dodatno izboljšati korporativno upravljanje ECB, Evropskega sistema centralnih bank (ESCB), Eurosistema in enotnega mehanizma nadzora (EMN).
Public awareness of corporate governance issues and of ethics rules has increased over recent years.
V zadnjih letih se je ozaveščenost javnosti o vprašanjih korporativnega upravljanja in etičnih pravilih povečala.
Following the establishment of the SSM, governance issues have acquired increased significance for the ECB.
Po vzpostavitvi EMN so vprašanja upravljanja za ECB še pomembnejša.
The increased level of public awareness and scrutiny requires the ECB to have in place, and strictly adhere to, state-of-the-art ethics rules in order to safeguard the ECB's integrity and avoid reputational risks.
Večja ozaveščenost in nadzor javnosti zahtevata, da ECB vzpostavi najsodobnejša etična pravila za zagotavljanje svoje integritete in preprečitev tveganj za svoj ugled ter se jih strogo drži.
The ethics rules for members of the bodies involved in the ECB's decision-making processes (hereinafter the ‘addressees’) should be based on the same principles that apply to ECB staff members and should be proportionate to the addressees' respective responsibilities.
Etična pravila za člane teles, ki sodelujejo v postopkih odločanja ECB (v nadaljnjem besedilu: naslovniki), bi morala temeljiti na istih načelih kot pravila, ki se uporabljajo za zaposlene v ECB, in bi morala biti sorazmerna z zadevnimi nalogami naslovnikov.
Therefore, the various rules constituting the ECB ethics framework, i.e. the Code of Conduct for the members of the Governing Council [2], the Supplementary Code of Ethics Criteria for the members of the Executive Board [3], the Code of Conduct for the members of the Supervisory Board and the ECB Staff Rules, should be interpreted in a coherent manner.
Zato bi bilo treba raznovrstna pravila, ki tvorijo etični okvir ECB, tj. Kodeks ravnanja za člane Sveta ECB [2], Dopolnilni kodeks meril poklicne etike za člane izvršilnega odbora Evropske centralne banke [3], Kodeks ravnanja za člane Nadzornega odbora in Pravila za zaposlene v ECB, razlagati skladno.